Literature DB >> 34126911

Solving the Gap Between HCV Detection and Treatment in Prison HCVRNA Testing and Treatment in a Cohort of Newly Arrived Convicts in Southern Italy.

Carmine Izzo1, Mario Masarone1, Pietro Torre1, Giuseppe Melara1, Giuseppe De Matteis2, Antonio De Luna3, Antonio Maria Pagano2, Marcello Persico1.   

Abstract

INTRODUCTION: HCV infection elimination is set to be carried out by 2030. To achieve this goal, the WHO has set minor achievable short-term "mini-goals." One of these is treating "difficult to reach and treat populations," such as prisoners. One of the biggest obstacles to achieving this mini goal is the poor knowledge of the real HCV prevalence in such a population and the barriers to its detection, treatment, and follow-up. Even if HCV testing in Italian prisons is feasible and recommended, it is not however always carried out. To worsen the picture, the peculiar status of conviction is correlated to difficulty in caring out the antiviral therapy due to loss in follow-up and to the refusals by inmates. AIMS: A point-of-care test-and-treat program was set up in a penitentiary in Southern Italy to reduce the number of patients Lost To Follow-Up (LTFU) between detection and treatment. A secondary aim was to evaluate the prevalence of HCV-infected patients in a cohort of newly arrived inmates.
METHODS: This prospective-observational study was carried out from January 2020 to February 2020. We performed an HCV-RNA blood capillary quick test on all newly arrived inmates. As a routine, the new inmates underwent clinical and laboratory assessments. To those who were detected HCV-RNA positive, the shortest possible antiviral treatment was offered, according to genotype and clinical features.
RESULTS: We observed 122 new inmates in the period between January and February of 2020. Overall, 62 (50.8%) subjects took HCV-RNA quick testing through blood sampling. Four (6.4%) subjects were found to be HCV-RNA positive; 1 refused antiviral therapy, while 3 accepted, obtaining 100% SVR. None of the HCV-active inmates were lost to follow up between detection and treatment proposal.
CONCLUSION: The use of a high-speed test-and-treat protocol for HCV infection was demonstrated to be effective in avoiding LTFU in HCV-positive new inmates in the period between detection and treatment. We observed an apparent prevalence of HCV incident cases in newly arrived inmates of 6.4%. Antiviral therapy was quickly provided and found to be effective and successful. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Direct antiviral agents; HCV infection; HCV treatment; people in conviction; point-of-care; sustained virologicalresponse.

Mesh:

Substances:

Year:  2021        PMID: 34126911     DOI: 10.2174/1574887116666210612033824

Source DB:  PubMed          Journal:  Rev Recent Clin Trials        ISSN: 1574-8871


  2 in total

1.  Not Only COVID-19: Prevalence and Management of Latent Mycobacterium Tuberculosis Infection in Three Penitentiary Facilities in Southern Italy.

Authors:  Carmine Izzo; Annunziata Monica; Giuseppe De Matteis; Sebastiana De Biasi; Anna De Chiara; Antonio Maria Pagano; Eleonora Mezzetti; Fabio Del Duca; Alice Chiara Manetti; Raffaele La Russa; Marco Di Paolo; Aniello Maiese
Journal:  Healthcare (Basel)       Date:  2022-02-18

2.  Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel.

Authors:  Vito Fiore; Giuseppe De Matteis; Emanuele Pontali; Andrea De Vito; Sandro Panese; Nicholas Geremia; Ivana Maida; Stefania Artioli; Giulio Starnini; Giordano Madeddu; Sergio Babudieri
Journal:  Front Public Health       Date:  2022-10-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.